drugset / Trial / NCT05373303

The Clinical Study for Evaluating The Safety And Efficacy Of Epodion®

NCT05373303 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The study was conducted to evaluate whether the efficacy and safety profile of recombinant human erythropoietin (rhEPO) manufactured by Daewoong Pharmaceutical Co., Ltd was similar to biological products approved by the drug safety regulatory authority.

Timeline

Start
2019-11-07
Primary completion
2021-05-15
Completion
2022-01-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Recombinant Human Erythropoietin Alpha Protein / enzyme biologic 50 iu/kg Intravenous